

# Accepted Manuscript

Control strategies for drug product continuous direct compression – state of control, product collection strategies, and startup/shutdown operations for the production of clinical trial materials and commercial products

Ahmad Almaya, Lawrence De Belder, Robert Meyer, Karthik Nagapudi, Hung-Ren Homer Lin, Ian Leavesley, Jayanthi Jayanth, Gurjit Bajwa, James DiNunzio, Anthony Tantuccio, Dan Blackwood, Admassu Abebe

PII: S0022-3549(16)41939-8

DOI: [10.1016/j.xphs.2016.12.014](https://doi.org/10.1016/j.xphs.2016.12.014)

Reference: XPHS 591

To appear in: *Journal of Pharmaceutical Sciences*

Received Date: 3 October 2016

Revised Date: 6 December 2016

Accepted Date: 7 December 2016

Please cite this article as: Almaya A, De Belder L, Meyer R, Nagapudi K, Lin HRH, Leavesley I, Jayanth J, Bajwa G, DiNunzio J, Tantuccio A, Blackwood D, Abebe A, Control strategies for drug product continuous direct compression – state of control, product collection strategies, and startup/shutdown operations for the production of clinical trial materials and commercial products, *Journal of Pharmaceutical Sciences* (2017), doi: 10.1016/j.xphs.2016.12.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## **Control strategies for drug product continuous direct compression – state of control, product collection strategies, and startup/shutdown operations for the production of clinical trial materials and commercial products**

Ahmad Almaya\*<sup>1</sup>, Lawrence De Belder<sup>2</sup>, Robert Meyer<sup>3</sup>, Karthik Nagapudi<sup>4</sup>, Hung-Ren Homer Lin<sup>5</sup>, Ian Leavesley<sup>1</sup>, Jayanthi Jayanth<sup>6</sup>, Gurjit Bajwa<sup>7</sup>, James DiNunzio<sup>3</sup>, Anthony Tantuccio<sup>8</sup>, Dan Blackwood<sup>9</sup>, Admassu Abebe<sup>8</sup>

---

\*Corresponding author (Telephone: 317-277-3680; Email: [Almaya\\_ahmad@lilly.com](mailto:Almaya_ahmad@lilly.com))

<sup>1</sup> Eli Lilly and Company; <sup>2</sup> Janssen Pharmaceutica NV; <sup>3</sup> Merck; <sup>4</sup> Genentech; <sup>5</sup> Amgen; <sup>6</sup> AbbVie; <sup>7</sup> Glaxo Smith Kline; <sup>8</sup> Bristol-Myers Squibb; <sup>9</sup> Pfizer

**Keywords:** Continuous Manufacturing, Direct Compression, Control Strategy, State of Control, Statistical Process Control, Process Capability

Download English Version:

<https://daneshyari.com/en/article/8514283>

Download Persian Version:

<https://daneshyari.com/article/8514283>

[Daneshyari.com](https://daneshyari.com)